{"id":39402,"date":"2025-08-15T14:27:40","date_gmt":"2025-08-15T06:27:40","guid":{"rendered":"https:\/\/flcube.com\/?p=39402"},"modified":"2025-08-15T14:27:41","modified_gmt":"2025-08-15T06:27:41","slug":"pfizers-emblaveo-prescribed-in-shanghai-hospitals-for-first-time-nationwide","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39402","title":{"rendered":"Pfizer’s Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide"},"content":{"rendered":"\n

US giant Pfizer Inc. (NYSE: PFE<\/a>) announced that its Emblaveo (aztreonam and avibactam) has been prescribed for the first time nationwide in several hospitals in Shanghai. The drug received approval from China’s National Medical Products Administration (NMPA) in June 2025 for treating adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.<\/p>\n\n\n\n

Drug Mechanism<\/strong>
Emblaveo is the first \u03b2-lactam\/\u03b2-lactamase inhibitor combination targeting bacteria producing metallo-\u03b2-lactamases (MBLs) and covering all enzyme types of carbapenem-resistant Enterobacterales (CRE). This combination provides a new treatment option for infections caused by multidrug-resistant Gram-negative bacteria.<\/p>\n\n\n\n

Clinical Significance<\/strong>
The launch of Emblaveo marks a significant breakthrough in China’s efforts to combat infections caused by multidrug-resistant Gram-negative bacteria. It ushers in a new era of precision medicine in anti-infective therapy, offering hope for patients with limited treatment options.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been…<\/p>\n","protected":false},"author":1,"featured_media":39403,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[40,863,309],"class_list":["post-39402","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-launch","tag-nyse-pfe","tag-pfizer"],"yoast_head":"\nPfizer's Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been prescribed for the first time nationwide in several hospitals in Shanghai. The drug received approval from China's National Medical Products Administration (NMPA) in June 2025 for treating adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39402\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer's Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide\" \/>\n<meta property=\"og:description\" content=\"US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been prescribed for the first time nationwide in several hospitals in Shanghai. The drug received approval from China's National Medical Products Administration (NMPA) in June 2025 for treating adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39402\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T06:27:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-15T06:27:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1506.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39402#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39402\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer’s Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide\",\"datePublished\":\"2025-08-15T06:27:40+00:00\",\"dateModified\":\"2025-08-15T06:27:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39402\"},\"wordCount\":164,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39402#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1506.webp\",\"keywords\":[\"Market launch\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39402#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39402\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39402\",\"name\":\"Pfizer's Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39402#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39402#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1506.webp\",\"datePublished\":\"2025-08-15T06:27:40+00:00\",\"dateModified\":\"2025-08-15T06:27:41+00:00\",\"description\":\"US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been prescribed for the first time nationwide in several hospitals in Shanghai. The drug received approval from China's National Medical Products Administration (NMPA) in June 2025 for treating adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39402#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39402\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39402#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1506.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1506.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer's Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39402#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer’s Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer's Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide - Insight, China's Pharmaceutical Industry","description":"US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been prescribed for the first time nationwide in several hospitals in Shanghai. The drug received approval from China's National Medical Products Administration (NMPA) in June 2025 for treating adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39402","og_locale":"en_US","og_type":"article","og_title":"Pfizer's Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide","og_description":"US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been prescribed for the first time nationwide in several hospitals in Shanghai. The drug received approval from China's National Medical Products Administration (NMPA) in June 2025 for treating adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.","og_url":"https:\/\/flcube.com\/?p=39402","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-15T06:27:40+00:00","article_modified_time":"2025-08-15T06:27:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1506.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39402#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39402"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer’s Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide","datePublished":"2025-08-15T06:27:40+00:00","dateModified":"2025-08-15T06:27:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39402"},"wordCount":164,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39402#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1506.webp","keywords":["Market launch","NYSE: PFE","Pfizer"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39402#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39402","url":"https:\/\/flcube.com\/?p=39402","name":"Pfizer's Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39402#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39402#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1506.webp","datePublished":"2025-08-15T06:27:40+00:00","dateModified":"2025-08-15T06:27:41+00:00","description":"US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been prescribed for the first time nationwide in several hospitals in Shanghai. The drug received approval from China's National Medical Products Administration (NMPA) in June 2025 for treating adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39402#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39402"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39402#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1506.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1506.webp","width":1080,"height":608,"caption":"Pfizer's Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39402#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer’s Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1506.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39402"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39402\/revisions"}],"predecessor-version":[{"id":39404,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39402\/revisions\/39404"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39403"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}